TherapeuticsMD (TXMD) Competitors $1.08 +0.03 (+2.36%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. ATNM, FGEN, TPST, VRCA, LTRN, PEPG, NBRV, RNXT, ATHE, and AADIShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Its Competitors Actinium Pharmaceuticals FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience TherapeuticsMD (NASDAQ:TXMD) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability. Is TXMD or ATNM more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -17.94%. TherapeuticsMD's return on equity of -2.01% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-17.94% -2.01% -1.40% Actinium Pharmaceuticals N/A -100.85%-47.89% Which has preferable earnings & valuation, TXMD or ATNM? TherapeuticsMD has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.76M7.13-$2.18MN/AN/AActinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.26 Which has more risk & volatility, TXMD or ATNM? TherapeuticsMD has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Do analysts rate TXMD or ATNM? Actinium Pharmaceuticals has a consensus price target of $4.50, indicating a potential upside of 173.56%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in TXMD or ATNM? 30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 2.3% of TherapeuticsMD shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor TXMD or ATNM? In the previous week, TherapeuticsMD's average media sentiment score of 1.00 beat Actinium Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the media. Company Overall Sentiment TherapeuticsMD Positive Actinium Pharmaceuticals Neutral SummaryTherapeuticsMD beats Actinium Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.38M$2.85B$5.79B$10.36BDividend YieldN/A59.99%5.86%4.62%P/E RatioN/A23.6176.8626.91Price / Sales7.13497.55450.9189.68Price / CashN/A169.8537.2260.63Price / Book0.465.4013.756.37Net Income-$2.18M$32.95M$3.29B$271.38M7 Day Performance-2.25%0.04%0.53%2.11%1 Month Performance-4.82%5.23%4.89%7.56%1 Year Performance-34.64%-1.53%83.74%31.10% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD1.2389 of 5 stars$1.09+2.4%N/A-38.4%$12.38M$1.76M0.00420Positive NewsShort Interest ↓ATNMActinium Pharmaceuticals2.4185 of 5 stars$1.60+1.3%$4.50+181.3%-11.5%$49.91MN/A-1.1530FGENFibroGen4.3805 of 5 stars$11.16-7.8%$43.00+285.3%-0.6%$48.93M$29.62M-29.37570Gap UpTPSTTempest Therapeutics1.7805 of 5 stars$10.85-1.3%$30.00+176.5%-51.2%$48.80MN/A-0.7420Gap UpVRCAVerrica Pharmaceuticals3.0538 of 5 stars$5.06-1.0%$80.00+1,481.0%-75.1%$48.22M$7.57M-0.6140Gap UpLTRNLantern Pharma2.0575 of 5 stars$4.06-5.8%$25.00+515.8%+2.6%$46.54MN/A-2.2820PEPGPepGen2.6476 of 5 stars$1.49+6.4%$7.67+414.5%-79.5%$45.92MN/A-0.5030NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.2122 of 5 stars$1.14-8.1%$7.50+557.9%+20.8%$45.44M$40K-3.006News CoverageNegative NewsShort Interest ↑ATHEAlterity Therapeutics2.0023 of 5 stars$5.17+2.0%$12.00+132.1%+247.9%$44.96MN/A0.0010High Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+6.0%$44.95M$25.07M-0.8040 Related Companies and Tools Related Companies Actinium Pharmaceuticals Alternatives FibroGen Alternatives Tempest Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Lantern Pharma Alternatives PepGen Alternatives Nabriva Therapeutics Alternatives RenovoRx Alternatives Alterity Therapeutics Alternatives Aadi Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TXMD Stock Alerts